<DOC>
	<DOCNO>NCT00006747</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy use kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow donor peripheral stem cell transplantation treat patient mantle cell lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Peripheral Stem Cell Transplantation Treating Patients With Mantle Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine long term disease-free survival patient mantle cell lymphoma treat etoposide , carmustine , melphalan , cytarabine follow allogeneic peripheral blood stem cell transplantation . - Determine incidence molecular remission patient treat regimen . - Correlate persistence minimal residual disease clinical outcome patient treat regimen . - Determine effect donor lymphocytes patient progressive disease treatment regimen . OUTLINE : This multicenter study . Patients receive carmustine IV 2 hour day -6 ; etoposide IV 3 hour cytarabine IV 1 hour every 12 hour day -5 -2 total 8 dos ; melphalan IV 20-30 minute day -1 . Patients undergo allogeneic peripheral blood stem cell ( PBSC ) transplantation day 0 . Patients also receive tacrolimus IV continuously 24 hour begin day -2 orally twice daily day 120 methotrexate IV 30 minute day 1 , 3 , 6 graft-versus-host disease ( GVHD ) prophylaxis . Patients receive sargramostim ( GM-CSF ) IV subcutaneously daily begin day 7 continue blood count recover . Patients active GVHD persistent disease day 150 progressive disease time PBSC transplantation receive donor lymphocyte IV 2 hour . Patients may receive additional donor lymphocytes least 8 week later disease persists . Patients follow 6 12 month posttransplantation annually 4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>1 . Documentation Disease 1 . Histologically documented mantle cell lymphoma stage ( needle core biopsy acceptable sole mean diagnosis ) least one follow confirmatory test indicative diagnosis : Immunophenotype expression CD5 CD19 absence CD23 Cytogenetic analysis presence ( 11 ; 14 ) Overexpression cyclin D1 Rearrangement BCL1 gene 2 . Rebiopsy node relapse recommend require . 3 . Bone marrow biopsy require pretreatment evaluation . Bilateral biopsy require . 2 . Identification HLAMatched sibling donor The sibling donor must meet eligibility criterion outline section 5.0 3 . Prior Therapy 1 . Patients fail initial therapy eligible ( without poor prognostic characteristic list protocol ) . Failure initial treatment define one following : Failure achieve clinical complete remission treatment anthracyclinecontaining regimen Disease recurrence initial treatment ( anthracyclinecontaining regimen ) 2 . Patients first remission must one follow poor prognostic characteristic : International Prognostic Index ( IPI ) score &gt; 1 . IPI risk factor include follow : age &gt; 60 ( eligible protocol ) ; performance status &gt; 1 ; LDH &gt; normal ; presence &gt; 1 extranodal site ; stage III/IV disease Blastic variant mantle cell lymphoma ( regardless IPI score ) Complex karyotype ( i.e. , cytogenetic abnormality different addition ( 11 ; 14 ) ( regardless IPI score ) Proliferative index &gt; 10 % ( regardless IPI score ) Presence p53 mutation 3 . Patients receive two chemotherapy regimen ineligible . Patients undergone prior bone marrow transplant eligible . 4 . Age &lt; 60 year 5 . No active CNS lymphoma 6 . DLCO ≥ 40 % symptomatic pulmonary disease 7 . No HIV infection 8 . Nonpregnant nonnursing . Treatment protocol would expose unborn child significant risk . Women men reproductive potential agree use effective mean birth control . 9 . Initial required laboratory value bilirubin &lt; 2 mg/dl AST ≤ 3 x upper limit normal ( ULN ) ALT ≤ 3 x ULN serum creatinine &lt; 2 mg/dl uHCG serum HCG negative ( patient childbearing potential )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
</DOC>